Seres Therapeutics Inc (MCRB) Stake Boosted by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP grew its stake in shares of Seres Therapeutics Inc (NASDAQ:MCRB) by 45.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,600 shares of the biotechnology company’s stock after acquiring an additional 11,488 shares during the quarter. Dimensional Fund Advisors LP owned about 0.09% of Seres Therapeutics worth $414,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. American International Group Inc. increased its holdings in shares of Seres Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 727 shares in the last quarter. Advisor Group Inc. increased its holdings in shares of Seres Therapeutics by 100.7% during the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 7,050 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in shares of Seres Therapeutics during the second quarter valued at about $169,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Seres Therapeutics during the second quarter valued at about $236,000. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Seres Therapeutics by 2.7% during the second quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 580 shares in the last quarter. Hedge funds and other institutional investors own 77.83% of the company’s stock.
Shares of Seres Therapeutics Inc (MCRB) opened at $9.87 on Wednesday. Seres Therapeutics Inc has a 52-week low of $8.85 and a 52-week high of $17.42. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11.
Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. The firm had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. Seres Therapeutics’s revenue for the quarter was up 76.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. equities analysts anticipate that Seres Therapeutics Inc will post -2.33 EPS for the current year.
Several equities analysts have recently issued reports on MCRB shares. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Tuesday. Seaport Global Securities reiterated a “buy” rating and issued a $20.00 target price on shares of Seres Therapeutics in a research report on Friday, October 6th. Cowen reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Monday, October 2nd. Cantor Fitzgerald reiterated a “buy” rating on shares of Seres Therapeutics in a research report on Wednesday, August 30th. Finally, BidaskClub lowered Seres Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. Seres Therapeutics currently has a consensus rating of “Buy” and an average target price of $18.00.
Seres Therapeutics Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.